Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Safe Supply Announces Proposed Acquisition of European Medical Testing Subsidiary (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News FibroGen Inc FGEN

Healthcare Biotechnology
FibroGen, Inc. is a biopharmaceutical company. The Company is engaged in developing and commercializing a diversified pipeline of novel therapeutics that work at the frontiers of cancer biology and anemia. Its clinical, commercial, and research programs include Pamrevlumab, which is a first-in-class antibody being developed by FibroGen to inhibit the activity of connective tissue growth factor ... see more

Recent & Breaking News (NDAQ:FGEN)

FGEN ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of June 11, 2021 in the Class Action Filed on Behalf of FibroGen, Inc. Limited Shareholders

Newsfile April 23, 2021

Kessler Topaz Meltzer & Check, LLP: Reminds Investors of Securities Fraud Class Action Filed Against FibroGen, Inc.

Newsfile April 23, 2021

Fibrogen Shareholder Alert

Newsfile April 23, 2021

HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages FibroGen (FGEN) Investors with Losses to Contact Its Attorneys Now, Securities Fraud Class Action Filed, Investor Deadline Established

Newsfile April 23, 2021

INVESTOR ACTION ALERT: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against FibroGen, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

ACCESSWIRE IA April 23, 2021

FGEN ALERT: ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages FibroGen, Inc. Investors with Losses Exceeding $100K to Secure Counsel Before Important Deadline - FGEN

ACCESSWIRE IA April 23, 2021

DEADLINE ALERT for DDD, DOX, SHRMF, and FGEN: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders

GlobeNewswire April 23, 2021

SHAREHOLDER ACTION ALERT: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against FibroGen, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

Newsfile April 23, 2021

FGEN Shareholder Alert: Bronstein, Gewirtz & Grossman, LLC Reminds FibroGen, Inc. Investors of Class Action and Encourages Investors to Contact the Firm

Newsfile April 23, 2021

FIBROGEN SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Reminds Investors with Losses in Excess of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against FibroGen, Inc. - FGEN

Newsfile April 22, 2021

Investor Alert: Kessler Topaz Meltzer & Check, LLP Reminds Investors of Securities Fraud Class Action Lawsuit Filed Against FibroGen, Inc. (FGEN)

ACCESSWIRE IA April 22, 2021

Fibrogen Investor Alert: Class Action Lawsuit Filed

Newsfile April 22, 2021

HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Updates ACAD, FGEN, RMO Investors on Securities Fraud Lawsuits, Encourages Investors with Losses to Contact the Firm

ACCESSWIRE IA April 22, 2021

SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KSF REMINDS DOX, FGEN, GOEV, MPLN INVESTORS of Lead Plaintiff Deadline in Class Action Lawsuits

GlobeNewswire April 21, 2021

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Champignon Brands, FibroGen, Canaan, and Credit Suisse and Encourages Investors to Contact the Firm

GlobeNewswire April 21, 2021

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of FibroGen, Inc. - FGEN

Newsfile April 21, 2021

Fibrogen Deadline Alert

Newsfile April 21, 2021

HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages FibroGen (FGEN) Investors with Losses to Contact Its Attorneys Now, Securities Fraud Class Action Filed and Important Deadline Established

Newsfile April 21, 2021

Class Action Alert: Kessler Topaz Meltzer & Check, LLP Reminds FGEN Investors for Securities Fraud Class Action Lawsuit

GlobeNewswire April 21, 2021

INVESTOR ACTION NOTICE: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against FibroGen, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

ACCESSWIRE IA April 21, 2021